{"nctId":"NCT05270863","briefTitle":"Safety and Efficacy Study BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic or Pseudophakic Presbyopia","startDateStruct":{"date":"2022-03-30","type":"ACTUAL"},"conditions":["Presbyopia"],"count":182,"armGroups":[{"label":"BRIMOCHOL™ PF","type":"EXPERIMENTAL","interventionNames":["Drug: BRIMOCHOL™ PF"]},{"label":"Carbachol PF","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Carbachol PF"]},{"label":"Brimonidine tartrate","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Brimonidine tartrate"]}],"interventions":[{"name":"BRIMOCHOL™ PF","otherNames":["carbachol/brimonidine tartrate"]},{"name":"Carbachol PF","otherNames":["carbachol monotherapy"]},{"name":"Brimonidine tartrate","otherNames":["brimonidine tartrate monotherapy"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female in good general health\n* Must have presbyopia\n\nExclusion Criteria:\n\n* History of allergic reaction to the study drug or any of its components\n* Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results","healthyVolunteers":true,"sex":"ALL","minimumAge":"45 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Proportion of Subjects With >=15 Letter Gain Without >=5 Letter Loss in Near Visual Acuity","description":"Primary endpoint measure at hour 1 post-dose at study visit","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.4","spread":null},{"groupId":"OG001","value":"35.0","spread":null},{"groupId":"OG002","value":"22.7","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":178},"commonTop":["Eye Irritation","Headache"]}}}